Marco Gallo
@marcogallo.bsky.social
Associate Prof at Baylor College of Medicine. Brain tumor research at Texas Children's Hospital. Houston, TX. 🇨🇦 in 🇺🇸
https://www.bcm.edu/research/faculty-labs/marco-gallo-lab
https://www.bcm.edu/research/faculty-labs/marco-gallo-lab
Congratulations, Daniel!
November 7, 2025 at 11:01 PM
Congratulations, Daniel!
Reposted by Marco Gallo
This week, that idea reached patients: Viral-mimicry priming + anti-PD-1 in relapsed/refractory NK/T-cell lymphoma delivered 47.6% complete responses, 66.7% ORR, and ~50% 2-year OS, even after prior PD-1 failure (Huang, Cancer Discovery 2025).
November 7, 2025 at 9:38 PM
This week, that idea reached patients: Viral-mimicry priming + anti-PD-1 in relapsed/refractory NK/T-cell lymphoma delivered 47.6% complete responses, 66.7% ORR, and ~50% 2-year OS, even after prior PD-1 failure (Huang, Cancer Discovery 2025).
Thanks to all collaborators, especially Dr Sameer Agnihotri at @news.upmc.com
November 7, 2025 at 2:42 PM
Thanks to all collaborators, especially Dr Sameer Agnihotri at @news.upmc.com